160 related articles for article (PubMed ID: 33501493)
1. Utility of Immunohistochemistry for MUC4 and GATA3 to Aid in the Distinction of Pleural Sarcomatoid Mesothelioma From Pulmonary Sarcomatoid Carcinoma.
Terra SBSP; Roden AC; Aubry MC; Yi ESJ; Boland JM
Arch Pathol Lab Med; 2021 Feb; 145(2):208-213. PubMed ID: 33501493
[TBL] [Abstract][Full Text] [Related]
2. GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung.
Berg KB; Churg A
Am J Surg Pathol; 2017 Sep; 41(9):1221-1225. PubMed ID: 28614203
[TBL] [Abstract][Full Text] [Related]
3. The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas.
Prabhakaran S; Hocking A; Kim C; Hussey M; Klebe S
Hum Pathol; 2020 Nov; 105():1-8. PubMed ID: 32888937
[TBL] [Abstract][Full Text] [Related]
4. MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
Amatya VJ; Kushitani K; Mawas AS; Miyata Y; Okada M; Kishimoto T; Inai K; Takeshima Y
Mod Pathol; 2017 May; 30(5):672-681. PubMed ID: 28128276
[TBL] [Abstract][Full Text] [Related]
5. GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis.
Piao ZH; Zhou XC; Chen JY
Virchows Arch; 2021 Aug; 479(2):257-263. PubMed ID: 33570661
[TBL] [Abstract][Full Text] [Related]
6. Sarcomatoid Mesothelioma: A Clinicopathological and Immunohistochemical Study of 64 Cases.
Oramas DM; Zaleski M; Moran CA
Int J Surg Pathol; 2021 Dec; 29(8):820-825. PubMed ID: 33939493
[TBL] [Abstract][Full Text] [Related]
7. Pleural mesothelioma classification update.
Beasley MB; Galateau-Salle F; Dacic S
Virchows Arch; 2021 Jan; 478(1):59-72. PubMed ID: 33475835
[TBL] [Abstract][Full Text] [Related]
8. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
Hattori Y; Yoshida A; Yoshida M; Takahashi M; Tsuta K
Pathol Int; 2015 Jun; 65(6):286-92. PubMed ID: 25727644
[TBL] [Abstract][Full Text] [Related]
10. TRPS1 outperforms GATA3 in pleural effusions with metastatic breast carcinoma versus mesothelioma.
Baban F; Koepplin JW; Ahmad M; Clarke-Brodber AL; Bois MC; Hartley CP; Sturgis CD
Diagn Cytopathol; 2023 Aug; 51(8):488-492. PubMed ID: 37096814
[TBL] [Abstract][Full Text] [Related]
11. Loss of Methylthioadenosine Phosphorylase by Immunohistochemistry Is Common in Pulmonary Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma.
Terra S; Roden AC; Yi ES; Aubry MC; Boland JM
Am J Clin Pathol; 2022 Jan; 157(1):33-39. PubMed ID: 34463336
[TBL] [Abstract][Full Text] [Related]
12. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.
Mawas AS; Amatya VJ; Kushitani K; Kai Y; Miyata Y; Okada M; Takeshima Y
Sci Rep; 2018 Jan; 8(1):134. PubMed ID: 29317712
[TBL] [Abstract][Full Text] [Related]
13. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.
Marchevsky AM; LeStang N; Hiroshima K; Pelosi G; Attanoos R; Churg A; Chirieac L; Dacic S; Husain A; Khoor A; Klebe S; Lantuejoul S; Roggli V; Vignaud JM; Weynard B; Sauter J; Henderson D; Nabeshima K; Galateau-Salle F
Hum Pathol; 2017 Sep; 67():160-168. PubMed ID: 28782639
[TBL] [Abstract][Full Text] [Related]
14. Pleural mesothelioma classification-update and challenges.
Dacic S
Mod Pathol; 2022 Jan; 35(Suppl 1):51-56. PubMed ID: 34465883
[TBL] [Abstract][Full Text] [Related]
15. Thoracic mesenchymal malignant tumors and programed cell death ligand-1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas.
Otsubo K; Sakai H; Kimura H; Miyazawa T; Marushima H; Kojima K; Furuya N; Mineshita M; Chosokabe M; Koike J; Saji H
Thorac Cancer; 2021 Dec; 12(23):3169-3176. PubMed ID: 34655161
[TBL] [Abstract][Full Text] [Related]
16. Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin.
Padgett DM; Cathro HP; Wick MR; Mills SE
Am J Surg Pathol; 2008 Jan; 32(1):123-7. PubMed ID: 18162779
[TBL] [Abstract][Full Text] [Related]
17. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
18. [Autopsy case of sarcomatoid malignant pleural mesothelioma].
Ogura H; Naoki K; Togashi I; Kunikane H; Okamoto H; Hida N; Narita Y; Kase M; Oosawa H; Oomori T; Watanabe K
Nihon Kokyuki Gakkai Zasshi; 2006 Oct; 44(10):689-94. PubMed ID: 17087333
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of MUC4 immunostaining in distinguishing epithelial mesothelioma and lung adenocarcinoma.
Llinares K; Escande F; Aubert S; Buisine MP; de Bolos C; Batra SK; Gosselin B; Aubert JP; Porchet N; Copin MC
Mod Pathol; 2004 Feb; 17(2):150-7. PubMed ID: 14657954
[TBL] [Abstract][Full Text] [Related]
20. Claudin-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4.
Naso JR; Churg A
Hum Pathol; 2020 Jun; 100():10-14. PubMed ID: 32333920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
